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Most intravascular catheter-related infections are associated with central venous catheters.
Technologic advances shown to reduce the risk for these infections include a catheter hub containing an
iodinated alcohol solution, short-term chlorhexidine-silver sulfadiazine-impregnated catheters, minocycline-
rifampin-impregnated catheters, and chlorhexidine-impregnated sponge dressings. Nontechnologic
strategies for reducing risk include maximal barrier precautions during catheter insertion, specialized
nursing teams, continuing quality improvement programs, and tunneling of short-term internal jugular
catheters.
Intravascular catheter-related bloodstream infections
are an important cause of illness and excess medical cost. In
prospective studies, the relative risk (RR) for a catheter-
related bloodstream infection is 2 to 855 times higher with
central venous catheters than peripheral venous catheters
(1-3). Approximately 80,000 catheter-related bloodstream
infections occur in U.S. intensive-care units each year, at a
cost of $296 million to $2.3 billion (4,5). These infections are
associated with 2,400 to 20,000 deaths per year. The focus of




Catheters impregnated with chlorhexidine-silver sulfa-
diazine are commercially available. In prospective, random-
ized studies of catheters left in place for an average of <11
days (6-14), the incidence of catheter-related bloodstream
infections was reduced by using chlorhexidine-silver
sulfadiazine-impregnated catheters (RR 0.4, confidence
interval [CI] 0.2-0.8) (4). These catheters are cost-effective if
the incidence of bloodstream infections is greater than 3.3/
1000 catheter-days (6) or greater than 1% (15). In addition, if
chlorhexidine-silver sulfadiazine-impregnated catheters in
place for <10 days reduce infections from 5.2% to 3%, then for
every 300 catheters used, approximately $60,000 would be
saved and seven catheter-related bloodstream infections and
one death would be prevented (15). Published studies of
chlorhexidine-silver sulfadiazine-impregnated catheters were
performed with catheters impregnated extraluminally.
However, the U.S. Food and Drug Administration (FDA) has
recently approved the use of catheters impregnated
intraluminally with chlorhexidine, in addition to
chlorhexidine-silver sulfadiazine extraluminal impregna-
tion. Use of chlorhexidine-silver sulfadiazine-impregnated
catheters has been associated with serious anaphylactoid
reactions in Japan (16), and these catheters are not
commercially available in that country. One such reaction in
the United States has been reported to the FDA (as of April
2000). Resistance to the antiseptic components of this device
has not been demonstrated in clinical studies (6). However, in
vitro studies of Pseudomonas stutzeri exposed to slowly
increasing concentrations of chlorhexidine, in the absence of
silver sulfadiazine, have demonstrated the development of
resistance to chlorhexidine and associated resistance to
several classes of therapeutic antimicrobial agents (17).
Although the conditions in these experiments do not simulate
clinical practice, the experiments demonstrate the potential
for resistance associated with use of these devices.
Minocycline-Rifampin-Impregnated Catheters
Catheters impregnated with minocycline and rifampin
are commercially available. In a prospective, randomized
clinical trial of catheters in place for an average of 6 to 7 days,
minocycline-rifampin-impregnated catheters were associated
with lower incidence of infection than chlorhexidine-silver
sulfadiazine-impregnated catheters (RR 0.1, CI 0-0.6) (18).
The active ingredients of the minocycline-rifampin-impreg-
nated catheters were on the extraluminal and intraluminal
surfaces of the device, whereas the active ingredients of the
chlorhexidine-silver sulfadiazine-impregnated catheters were
only on the extraluminal surface. Therefore, the difference in
the incidence of infection may reflect the extent of
impregnation on the catheters, in addition to the difference in
active ingredients. If minocycline-rifampin-impregnated
catheters reduce infections from 5% to 0%, then for every 850
catheters used, approximately $500,000 would be saved (19).
Resistance to active antimicrobial components of the
minocycline-rifampin-impregnated catheters has not been
demonstrated in clinical studies (18,19). However, when
these catheters were implanted for 7 to 14 days in laboratory
animals and then removed and placed on agar plates injected
with Staphylococcus aureus, microbial growth was detected in
the zones of inhibition (20); this growth may represent
subpopulations of S. aureus with reduced susceptibility to
minocycline or rifampin. In additional experiments,
minocycline-rifampin-impregnated catheters were implanted
in animals for 7 days, after which rifampin-resistant,
minocycline-susceptible S. epidermidis was introduced into
the insertion site and tunnel tract. In this animal model, the
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minocycline-rifampin-impregnated catheters were not pro-
tective (20). These studies suggest the potential for resistance
against the antimicrobial agents used to impregnate these
catheters as their clinical use becomes more widespread.
Catheter Hubs Containing
Iodinated Alcohol
A catheter hub containing an antiseptic chamber filled
with 3% iodinated alcohol is commercially available in Europe
but not in the United States. In a prospective, randomized
trial of catheters in place for an average of 15 to 16 days, use
of a hub with the antiseptic chamber reduced the incidence of
infection (RR 0.2, CI 0.1-0.7) (21). A formal cost-benefit
analysis has not been published. However, use of this device
led to fourfold reduction in the incidence of infections, and the
device would most likely be cost-effective when used with
central venous catheters in place for approximately 2 weeks.
A minute amount of iodine (0.024 mg) is estimated to enter
the bloodstream each time the hub containing the antiseptic
chamber is punctured (21). However, the currently marketed
device has been modified, and entry of iodine into the
bloodstream with daily use has not been reported.
Chlorhexidine-Impregnated
Sponge Dressings
Use of a commercially available chlorhexidine-impreg-
nated sponge dressing at the insertion site of central venous
and arterial catheters led to a threefold reduction in catheter-
related bloodstream infections in a recent prospective,
randomized study (22).
Nontechnologic Interventions
Several strategies reduce the risk for catheter-related
bloodstream infection. In a prospective, randomized study of
central venous catheter insertion, use of maximal barrier
precautions (large sterile sheet drape; long-sleeved sterile
gown; sterile gloves, mask, and hat) resulted in lower
incidence of infections, 0.08/1,000 catheter-days, compared
with use of minimal precautions (small sterile drape and
sterile gloves), 0.5/1,000 catheter-days (23). In another
prospective, randomized trial of peripheral catheter
insertions, the catheters inserted and managed by a
specialized nursing team had a lower incidence of infection
than catheters inserted and managed by house officers (odds
ratio 0, CI 0-0.6 [24]). In prospective, cohort studies,
continuing quality improvement programs aimed at
appropriate insertion and maintenance of catheters
substantially reduced the incidence of infection (25-29). In a
prospective, randomized trial of catheters not used for blood-
drawing, tunneling of short-term internal jugular central
venous catheters was associated with lower incidence of
infection than nontunneling of catheters (RR 0.2, CI 0.1-0.7
[30]).
Some of the nontechnologic interventions aimed at
reducing the risk for catheter-related bloodstream infection,
such as quality improvement programs, depend on changes in
human  behavior. Once implemented, whether they remain
effective over the long term remains to be seen.
Future Strategies
Greater understanding of the pathogenesis of intravascu-
lar-related infections will help prevent such infections. For
example, S. aureus binding to the catheter surface in vivo
involves fibronectin-specific adhesions (31). Identification of
epitopes in the S. aureus fibronectin-binding protein for the
generation of adhesion-blocking antibodies (32) may aid in
preventing future infections. The development of bacterial
biofilms on the surface of foreign bodies involves cell-to-cell
signaling by acyl homoserine lactone-based chemical
messengers that control bacterial gene expression (33,34).
Prevention of microbial growth on the surface of future
intravascular catheters may be mediated by inhibitors of
these chemical messengers (35).
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